Paper Details

  1. Home
  2. Paper Details

Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.

Author: Aballay SoterasGabriel, AdroverRaul, AndersMargarita, AravenaEdmundo, CartierMariano, CoccozellaDaniel, FerradaAlejandro, GallardoPatricia E, GruzFernando, HaddadLeila, HernándezNelia, MendizabalManuel, MuñozAlberto, PeraltaMirta, PoncinoDaniel, PrietoJhon, Pérez RavierRoberto, ReggiardoMaria V, RidruejoEzequiel, RobleroJuan P, RomeroGustavo, RufAndres E, SilvaMarcelo O, SozaAlejandro A, VarónAdriana, VorobioffJulio, VujacichClaudia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This real-world study evaluated the safety and effectiveness of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) therapy for genotype 1 chronic hepatitis C infection in Latin America. The treatment was highly effective in patients without cirrhosis or with Child-Pugh A cirrhosis, but adverse events were more frequent in patients with Child-Pugh B cirrhosis or previous hepatic decompensation.
Paper Details　
Original Abstract of the Article :
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real-world setting. We analyzed a cohort of patients with ge...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/jmv.24816

データ提供：米国国立医学図書館（NLM）

Ombitasvir/paritaprevir/ritonavir/dasabuvir: A New Oasis in the Desert of Hepatitis C

Hepatitis C virus (HCV) infection can be a challenging condition, like trying to survive a long trek across a scorching desert. This research explores the effectiveness of a new treatment combination – ombitasvir/paritaprevir/ritonavir/dasabuvir (OBV/PTV/r/DSV) – in treating HCV infection in patients from Latin America. The study analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV, with or without ribavirin. The results showed that OBV/PTV/r/DSV was highly effective in achieving sustained virological response (SVR) in patients with chronic HCV without cirrhosis or with compensated cirrhosis. This combination is like a well-stocked caravan, providing a safe and effective path toward recovery.

A New Road to Recovery: Ombitasvir/paritaprevir/ritonavir/dasabuvir for Hepatitis C

This study suggests that OBV/PTV/r/DSV is a safe and effective treatment option for patients with HCV infection. It's like discovering a new, paved road through the desert, making the journey to recovery smoother and less arduous.

Navigating the Desert of Hepatitis C: Hope for Patients in Latin America

This research provides valuable information about the effectiveness of OBV/PTV/r/DSV for patients with HCV in Latin America. It's like finding a map that guides us to a safe and accessible oasis in the middle of a vast desert.

Dr.Camel's Conclusion

This research showcases the effectiveness of OBV/PTV/r/DSV in treating HCV infection in patients from Latin America. This combination is a promising tool in the fight against HCV, offering a ray of hope in the desert of viral infections.

Date :
  1. Date Completed 2018-03-20
  2. Date Revised 2019-01-06
Further Info :

Pubmed ID

28370222

DOI: Digital Object Identifier

10.1002/jmv.24816

Related Literature

Article Analysis
・Side Effects of ombitasvir paritaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.